Alliancebernstein L.P. Sells 200,928 Shares of Genmab A/S (NASDAQ:GMAB)

Alliancebernstein L.P. trimmed its stake in Genmab A/S (NASDAQ:GMAB) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,935,224 shares of the company’s stock after selling 200,928 shares during the period. Alliancebernstein L.P. owned approximately 2.26% of Genmab A/S worth $311,698,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of GMAB. Charles Schwab Investment Management Inc. raised its position in shares of Genmab A/S by 94.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock valued at $636,000 after buying an additional 12,654 shares in the last quarter. AIMZ Investment Advisors LLC purchased a new stake in Genmab A/S during the fourth quarter valued at about $3,525,000. HighTower Advisors LLC bought a new stake in Genmab A/S during the third quarter worth about $273,000. Verition Fund Management LLC purchased a new position in shares of Genmab A/S in the 3rd quarter worth about $709,000. Finally, FMR LLC increased its position in shares of Genmab A/S by 13.5% during the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock valued at $6,782,000 after purchasing an additional 33,076 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Price Performance

NASDAQ GMAB opened at $19.58 on Tuesday. Genmab A/S has a 1 year low of $18.64 and a 1 year high of $30.50. The stock has a market capitalization of $12.96 billion, a PE ratio of 11.25, a PEG ratio of 2.65 and a beta of 0.98. The business’s 50-day moving average is $20.87 and its 200 day moving average is $21.79.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. As a group, equities research analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GMAB has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research note on Thursday, February 13th. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. Finally, Truist Financial reduced their price objective on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday, March 11th. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Genmab A/S has an average rating of “Moderate Buy” and a consensus target price of $41.33.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.